

1084 Lee Rd, Suite 4, Orlando, FL 32810

ate Medication Neede 1: Patient In	ed: Ship To: P	atient's Home Preso	criber's Office Pick-up (store location):	Injectior by pha	n training irmacv?
	TOTTIALION	Distributes a	Com Male Forcels Unitable Wei		h- l
Patient Name:				ght:	bs. kg.
Soc. Sec. #: Preferred Phone:			Known Allergies:		
				: Zip: _	
	ame:		Preferred Phone:		
2: Prescribe		e fax FRONT and BA	ACK copy of ALL Insurance cards (Prescription and Me	dical)	
Provider Name:	Tillorillation		DEA#: NPI#:	Tax ID#:	
Address:			Phone: Fax:		
City, State, Zip:			Key Contact: Phone:		
45					
			nical notes, Labs, Tests, with the prescription to expedi	te the Prior Auti	norizatio
•	ltiple Sclerosis Other:		Number of relapses in past year:		
	previously treated for this condition				,
Prior failed medication	n (medication and duration of treatment)	reason for d/c):	Inection training completed by: Novantrone:		
Patient currently on th	nerapy? Yes No Medication(s)		Is patient's LVEF <50%? Yes No		
	g above medication before starting		What is lifetime (cumulative) Novantrone dose (mg/m2)?		
	Discontinuation Date:		Copy of last CBC with differential:		
	gist? If no, please include neurolog		Is patient pregnant, nursing or planning pregnancy?		
Diagnosis:	Othor	, consult if available.	Serum Creatine Creatinine Clearance		
	on Information		-		
Medication	Dose/Strength		Sig	Qty.	Refills
Wicalcation	Dose/ser engen	Dose Titration:	5.5	4.3.	
Avonex*	AVOSTARTGRIP Titration Kit	• Week 1: Inject 7	7.5mcg IM once weekly	0	
	30mcg Prefilled Syringe #4 30mcg Pen #4	Week 2: Inject 15mcg IM once weekly Week 3: Inject 22.5mcg IM once weekly Week 4+: Inject 30mcg IM once weekly Week 4+: Inject 30mcg IM once weekly		4 week supply	
		Inject 30mcg IM one	ect 30mcg IM once weekly		
		Dose Titration:			
		• Weeks 1-2: Injec	ct 0.0625mg/0.25ml subcutaneously QOD		0
		• Wooks E 6: Inio	Weeks 3-4: Inject 0.125mg/0.50ml subcutaneously QOD Weeks 5-6: Inject 0.1875mg/0.75 subcutaneously QOD Weeks 7+: Inject 0.25mg/1ml subcutaneously QOD Maintenance Dose: 0.25mg /1ml subcutaneously QOD Other:		
Betaseron®	0.3mg vial	• Weeks 7+: Injec			
		Maintenance Dose			
		Othorn			
	20mg Prefiled Syringe	20mg SQ QD			
Copaxone [®]	40mg Prefiled Syringe		week, at least 48 hours apart on the same 3 days each week	4 week supply	
	3 7 0	Dose Titration:			
Extavia®	0.3mg vial	• Weeks 1-2: Injec	ct 0.0625mg/0.25ml subcutaneously QOD		0
			 Weeks 3-4: Inject 0.125mg/0.50ml subcutaneously QOD Weeks 5-6: Inject 0.1875mg/0.75 subcutaneously QOD 		
		Weeks 7+: Inject 0.25mg/1ml subcutaneously QOD		4 week supply	
		Maintenance Dose	Maintenance Dose: 0.25mg /1ml subcutaneously QOD		
		Other:			
Glatopa®	20mg Prefiled Syringe	20mg SQ QD		4 week supply	
Gilenya®	0.5mg capsule	Take 0.5mg po QD		4 week supply	
	,		utaneously three times a week weeks 1-2,		
		22mcg subcutaneously three times a week weeks 3-4, and			_
Rebif®	11tr d t t t t t t t t t t t t t t t t t t		neously three times a week weeks 5+ (48 hours apart)		0
Pohif Podidoso®	22mcg Prefilled Syringe		t 22mcg (0.5ml) SQ three times a week (48 hours apart)	4 week supply	
Rebif Redidose®	44mcg Prefilled Syringe	Maintenance: Injec	tt 44mcg (0.5ml) SQ three times a week (48 hours apart)		
		Other:			
PRIOR AUTHORI	ZATION APPLICATION TO IN	SURANCE AND PA	ATIENT SUPPORT PROGRAM ARE AVAILABLE AT	PROCARE PHA	ARMAC
	Prescri	oer Signature: Pres	scriber, please sign and date below		
spansa as written		Date	Substitution Permissable	Data	
spense as written		Date		Date	
ORTANT NOTICE: This fax is intend	ded to be delivered only to the named addressee and disseminate, distribute, or copy this fax. Please notify t	contains confidential information t	that may be protected health information under federal and state laws. If you		